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Purpose: The aim of the present study was to describe the purchasing patterns of a set of
antibiotics used exclusively in an out-patient pediatric setting in Italy using the Farma360
wholesale drug database (IQVIA Solutions Italy), identifying the proportion of medications
which are not captured by Italian National Health Service (NHS) pharmacy claims
databases and examining the implications of such findings from a public health and
pharmaceutical policy perspective.
Methods: Using a systematic approach, sixty-six antibiotic pediatric formulations were
selected for the 5 most commonly used antibiotics in Italy in children and adolescents:
amoxicillin in combination with clavulanic acid, amoxicillin, azithromycin, clarithromycin
and cefixime. The Farma360 wholesale drug purchasing database was used to identify
the yearly proportion of antibiotics not purchased based on NHS reimbursement in
primary care from 2015–2017 at the national level. The relationship between product cost
and purchase outside the NHS was assessed by a scatterplot. All analyses were stratified
by geographic area: Northwest, Northeast, Central and Southern Italy.
Results: The proportion of antibiotics not reimbursed by the NHS increased nationally from
24% in 2015 to 29% in 2017. The antibiotic with the highest proportion of purchases
outside the NHS was amoxicillin, with almost two-thirds of all amoxicillin purchases in
Southern Italy being made in this way in 2017. The relationship between antibiotic price and
antibiotic purchase outside the NHS was almost linear for many geographic areas.
Conclusions: This study showed that a large proportion of antibiotics with a pediatric
formulation is purchased outside the NHS drug purchasing pathway, especially in
Southern Italy, indicating that it is not possible to fully monitor drug utilization, including
appropriateness, for these antibiotics. A better strategy is needed to improve drug
utilization monitoring, such as better data collection or data linkage.
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A meta-analysis of pediatric pharmacoutilization studies
conducted in several countries around the world showed that
around 60% of children are exposed to medications yearly, the
majority of which (33%) were antibiotics (Clavenna and Bonati,
2009). This trend is also seen in Italy, with the prevalence of use
in the community setting varying from 43% in Southern Italy to
70% in Northern Italy (Piovani et al., 2013). Although
inappropriate antibiotic use is a widely acknowledged problem,
the unnecessary use of antibiotics, especially in viral infections,
still persists today. Indeed, one third of all antibiotics prescribed
in the US are considered to be unnecessary, and it is estimated
that half of all respiratory tract infections in the US are treated
unnecessarily with an antibiotic (Fleming-Dutra et al., 2016).
Inappropriate use of antibiotics in children is of high public
health interest because of increasing antibiotic resistance, in
addition to causing preventable adverse drug reactions and
costs (Hersh and Kronman, 2017). The inappropriate use of
antibiotics is driven by various factors which include but are
not limited to poor prescribing practices and self-medication
without a prescription (Lescure et al., 2018). Self-medication
without a prescription is arguably an important point for public
health intervention. All these issues highlight the need for
systematic and thorough monitoring of antibiotic purchasing
patterns. Indeed, previously published work shows the
importance of studying antibiotic consumption through
medication sales databases (Van Boeckel et al., 2014).
Antibiotic purchasing in Italy can occur via several pathways,
which can be summarized as the National Health Service (NHS)
drug purchasing pathway and non-NHS drug purchasingFrontiers in Pharmacology | www.frontiersin.org 2pathway (Figure 1). A national report on antibiotic utilization
in Italy showed that 17% of all antibiotic purchasing in the
general population occurs outside the NHS drug purchasing
pathways, i.e. is out-of-pocket (OsMed Report, 2019). This way
of purchasing medications was twice as high in Northern Italy
compared to Southern Italy (24% vs. 12%). However, there was
no information on antibiotics used in children specifically. This
constitutes an important knowledge gap concerning drug
utilization trends in Italy among children, whether at the
national level or by specific geographic area, as it is known
that drug utilization in Italy has strong variations in different
geographical area (Piovani et al., 2013).
Antibiotic purchasing pathways also have important
implications for pharmacoepidemiology studies conducted
using Italian NHS pharmacy claims databases, which leverage
data concerning medications purchased through the NHS (Trifirò
et al., 2019). Pharmacy claims data are very useful to study drug
utilization compared to electronic medical records, because they
are a step closer to confirming drug exposure, as patients having a
prescription may not fill it at the pharmacy. However, pharmacy
claims only capture medication dispensing based on the presence
of an NHS prescription (Youngster et al., 2017). The inability to
capture out-of-pocket purchasing of medications has often been
cited as a limitation of such studies (Piovani et al., 2013) but the
underestimation has never been quantified. The aim of the
present study was to describe purchasing patterns of a set of
antibiotics used exclusively in an outpatient pediatric setting in
Italy, identifying the proportion of medications which are not
captured by Italian NHS pharmacy claims databases and
examining the implications of such findings from a public
health and pharmaceutical policy perspective.FIGURE 1 | Antibiotic purchasing pathways in Italy. NHS, National Healthcare System.August 2020 | Volume 11 | Article 1232
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Setting
The present study is based in an Italian community setting,
where pediatric primary care is provided by the family
pediatrician (FP) within the NHS, for all children up to 14
years of age, thereafter by general practitioner (GP) (Ferrajolo
et al., 2017). Therefore, the majority of prescriptions for children
should be issued by NHS pediatricians in the community setting,
using an NHS prescription. Medications prescribed through
other medical specialists in their private practice would also be
covered by the NHS, provided that they issue an NHS
prescription which is used to purchase the medication.
However, specialists in a private practice can also write non-
NHS prescriptions, i.e. prescriptions which do not entitle
patients to reimbursement.
In Italy, all antibiotics for systemic administration used in the
primary care setting are covered by the NHS, either at directly the
time of purchase or after the purchase by reimbursing the patient
(Clavenna and Bonati, 2011). The patient is required to co-pay
part of the medication price for all medications, unless they are
exempt because of low income or because they have a diagnosis of
a chronic disease. In addition to the co-pay, patients are required
to pay the difference between a generic and non-generic
medication if they choose to buy a non-generic medication.
Practically, all antibiotics for systemic use in Italy should be
captured by NHS claims data if they are purchased with an
NHS prescription and then reimbursed by the NHS after a
claim is made, in line with national antibiotic dispensing
policies. Purchases made with an NHS prescription and
captured as NHS pharmacy claims were therefore considered to
denote antibiotics purchased within a nationally approved and
regulated prescribing pathway with a high degree of transparency
and traceability. All other types of antibiotic purchases were
considered to be made in an unidentifiable prescribing pathway
and cannot be monitored. Such purchasing pathways have very
limited transparency and traceability.
Data Sources
Nationally representative pharmacy sales data from Farma360, a
database owned by a commercial company, IQVIA, was
extracted from 2015 to 2017 using IMS Dataview 7.0. This
database contains aggregate information on the number of
drug packages sold to and bought from a sample of
community pharmacies from four macro-areas in Italy
covering all Italian regions. This sample comprises a minimum
of 5 and a maximum of 10 community pharmacies in every
region. The data collected allows the distinction between
medications which are not sold through the NHS drug
purchasing pathway (i.e. may or may not be purchased with a
prescription, NHS or otherwise, but not reimbursed by the NHS)
from those which are (i.e. definitely purchased with an NHS
prescription with subsequent reimbursement). Drug data in IMS
is coded using the Anatomic Therapeutic Chemical classification
code (ATC) and by a National Drug Code (NDC), known in Italy
as Autorizzazione all’Immissione in Commercio code. The NDCFrontiers in Pharmacology | www.frontiersin.org 3is specific for strength, formulation, route of administration and
manufacturer. The dispensing information in the database
contains the geographical area where the drug was purchased.
This database does not contain patient-level or aggregate-level
information on patient age, sex and medical history. To our
knowledge, this is the first paper to publish findings from the use
of the Farma360 database in Italy.
Study Population
The demographic and socioeconomic status of the catchment
areas was extracted from publically available information on the
Italian National Statistics Office using the latest available data
(https://www.istat.it/en/). Specifically, the age and sex
distribution for children aged up to 14 was extracted across all
catchment areas up until 2019. To describe the socioeconomic
status of the parents/families within the catchment areas, the
mean income per family in each Italian macro-area in 2017,
extracted from the latest available data (2017) of the Italian
National Statistics Office. In addition, information on the
number of persons aged 15 and over with specific categories of
education level was extracted from the Italian National Statistics
Office for the year 2019. The education levels available were:
completion of primary school, secondary school, vocational
school, high school or tertiary education (graduate or post-
graduate degree).
Study Drugs
Medicinal products intended exclusively for pediatric use
available on the market between 2015 and 2017 were identified
systematically by a clinical pharmacologist specialising in
pediatric pharmacology. First, the five most commonly used
antibiotics in the Italian pediatric population were identified
from the Italian National Report on Drug Utilization report
(OsMed, 2015): amoxicillin, amoxicillin–clavulanic acid
combination (i.e. co-amoxiclav) cefixime, azithromycin and
clarithromycin. Secondly, the NDCs of all the medicinal
products marketed in Italy corresponding to these five
antibiotics were identified using a national medicines database,
Farmadati. This database contains information (including NDC)
concerning the medicinal products currently available on the
market in Italy as well as for those which have been discontinued.
A total of 288 NDCs referring to selected antibiotics were
identified. Thirdly, among the 288 NDCs, formulations
intended specifically for children were identified based on their
formulations (e.g. syrups, solutions/power for reconstitution,
chewable tablets, suppositories etc.) and strength (i.e., the
amount of active substance per package), in particular those
having lower strength intended for children and the indication
“for children” as specified on the packaging and leaflet. After this
phase of screening, 66 NDCs specific for medicinal products with
pediatric formulations were identified. The list of medications
included in the study is available in Supplementary Material
Table 1. The prices for these medicinal products fixed by the
NHS were obtained separately for each year from the Italian
National Drug Agency website, to account for potential change
in price (https://www.aifa.gov.it/liste-di-trasparenza).August 2020 | Volume 11 | Article 1232
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All statistical analyses were conducted exclusively considering
medicinal products with pediatric formulations. The percentage of
medicinal product units purchased through the NHS drug purchasing
pathway and the percentage of medicinal product units which were
not purchased in this way was estimated for the 66medicinal products
having a pediatric formulation using 2015, 2016, and 2017 data at the
national level. Results were grouped by fifth level ATC and were also
graphically represented by horizontal stacked bar charts.
The distribution of purchases made through the NHS drug
purchasing pathways and other purchasing pathways in Italy was
then stratified by four macro-areas, i.e. Northeast Italy,
Northwest Italy, Central Italy and Southern Italy. The regions
included in each macro-area are reported in Supplementary
Material Table 2. This was done as drug utilization patterns in
Italy are known to vary significantly in these macro-areas
(OsMed Report, 2015); the population living in the same
macro-area shares the same demographic characteristics
influencing disease pattern and drug intake.
The proportion of antibiotics purchased outside the NHS drug
purchasing pathways (i.e. number of antibiotic purchases without
NHS reimbursement divided by all antibiotic purchases) were
described using box plots. The distribution of single drug product
purchasing patterns was evaluated, based on the NDC and clustered
at the ATC fifth level, and reported in box plots as minimum, first
quartile, median, third quartile, and maximum number of
purchases for each fifth level ATC. The central rectangle spans
the first quartile to the third quartile (i.e. the interquartile range or
IQR). The segment inside the rectangle shows the median and
“whiskers” (above and below each box) show the locations of the
minimum and maximum. These descriptive analyses were carried
out at the national level and by geographic area. The presence of a
statistical difference between yearly median percentage of antibiotic
purchase without prescription, as well as between the total number
of antibiotics bought with and without an NHS prescription was
tested using the Friedman rank sum test, i.e. non-parametric
repeated measures ANOVA.
To assess the relationship between antibiotic purchases occurring
outside the NHS drug purchasing pathways and medicinal product
prices, a scatterplot fitted through a Locally Estimated Scatterplot
Smoothing (LOESS) curve was carried out overall and stratified by
geographic area (Cleveland et al., 1979). Furthermore, to statistically
quantify the strength (and the direction) of the relationship between
the purchase of any of the five study antibiotics outside the NHS
antibiotic purchasing pathway and costs, Spearman’s rank
correlation coefficients were estimated.
All statistical analyses and plots were carried out using R
Foundation for Statistical Computing (version 3.6, packages:
ggplot2, gridExtra). P-values lower than 0.05 were considered
to denote statistical significance.RESULTS
The demographic and socioeconomic status of the population in
the catchment areas are presented in Supplementary MaterialFrontiers in Pharmacology | www.frontiersin.org 4Table 3 and Supplementary Material Figures 1 and 2. These
data show that there is no difference in the sex and age
distribution from Northeast/Northwest to Southern Italy, while
there is a strong gradient of decreasing mean family income from
Northeast/Northwest to Southern Italy as well as decreasing
education levels from Northeast/Northwest to Southern Italy
for persons aged 15 and over.
Overall, 66 medicinal products corresponding to the 5 most
commonly used antibiotics were selected. On average, 27% of
any of the 5 antibiotics medication were purchased outside the
NHS drug purchasing system from 2015 to 2017. There was a
modest increase in the purchase of antibiotics outside the NHS
system, from 24% in 2015 to 29% in 2017. There were notable
differences in the trends for single active ingredients. The
antibiotic drug most commonly purchased out-of-pocket was
amoxicillin (approximately 40% over the 3 study years), followed
by co-amoxiclav, azithromycin, cefixime and clarithromycin
(approximately 20% from 2015-2017). These trends remained
constant over the study period (Figure 2).
On stratifying results by geographic area, a temporal and
geographic trend in the purchase of antibiotics for children
outside the NHS drug purchasing pathway was often seen
based on the median and IQRs (Figure 3), with respective p-
values reported in Supplementary Material Table 4. Amoxicillin
was the drug most commonly purchased outside the NHS
purchasing pathway throughout the study period. This was
more marked in Southern Italy, where almost two thirds of
this drug were purchased outside the NHS purchasing pathway
from 2015 (58.7%; IQR: 55.2–63.6%) to 2017 (61.9%; IQR: 60.1–
63.3%). The greatest increase in out of pocket purchase for
amoxicillin over time was seen in Central Italy, where this
increased from 34.6% (IQR: 31.8–51.9%) in 2015 to 49.3%
(IQR: 41.0–54.2%) in 2017 (p-value: 0.011). Medications
containing azithromycin were among the least commonly
purchased drugs outside the NHS, ranging from 17.65% (IQR:
12.9–19.0%) to 23.5 (IQR: 20.8–33.2%) from Northeast and
South Italy in 2017, respectively. The overall trend for all five
antibiotics suggested that there was a slightly greater tendency to
purchase these drugs outside the NHS purchasing pathways in
the South of Italy compared to the North. For example, in 2017,
21.2% (IQR: 14.9–34.8%) and 21.2% (IQR: 15.7–29.4%) of
antibiotics were purchased outside the NHS purchasing pathway
in North eastern and North western Italy, respectively, while
26.4% (IQR: 20.3–38.4%) and 27.3% (IQR: 20.4–44.6%) did this in
central and Southern Italy, respectively. The distributions of the
number of packages underlying these proportions for antibiotics
purchased outside the NHS purchasing pathways and those
purchased within the NHS drug purchasing pathway are
consistent (data not shown).
As shown by the scatterplots and LOESS curves (Figure 4),
the relationship between antibiotic price and antibiotic purchase
outside the NHS drug purchasing pathway was markedly not
linear (u-shaped) in Central Italy and was almost linear for the
other geographic areas (Figure 4). All the relationships seen
between the purchase of antibiotics outside the NHS drug
purchasing pathway suggested that the lower the prices, theAugust 2020 | Volume 11 | Article 1232
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shown by Spearman’s coefficient, which was always negative
(Supplementary Material Table 5). The strongest trends were
seen in Southern Italy, where a statistically significant negative
correlation was seen in each year (<0.0001). Furthermore, the
strength of this correlation increased over the years in Southern
Italy, from a Spearman’s coefficient of −0.58 in 2015 to −0.72 in
2017. The weakest correlations were seen in Northwest Italy,
where the Spearman’s coefficient was −0.23 in 2017, suggesting
that the relationship between drug price and the purchase of
antibiotics outside the NHS drug purchasing pathway was less
strong in this area.DISCUSSION
The present study is the first to describe the extent of pediatric
antibiotic purchasing patterns in Italy as occurring through a
regulated and, therefore, traceable and transparent pathway or
otherwise. We have estimated that at the national level, around
one third of antibiotics for children were purchased outside the
NHS drug purchasing pathway and this proportion increased
modestly from 2015 to 2017. This finding is of relevance to all
pharmacoepidemiologic studies conducted using Italian claims
databases (De Bie et al., 2015; Piovani et al., 2016; Putignano
et al., 2017; Ferrajolo et al., 2019), because our findings suggest
that these studies may underestimate the use of antibiotics at
least by 30%; for specific antibiotics in certain catchment areas,
for example, amoxicillin in Southern Italy, this may be as high as
60%. While the extent of underestimation may vary for specific
drug classes and for different populations, this is the first time
that the issue is quantified; previous studies only allude to it, even
suggesting that it is likely to be minimal (Piovani et al., 2013).
The main strength of these Italian claims-based studies is theirFrontiers in Pharmacology | www.frontiersin.org 5population-based setting, where all contact with the NHS is
captured as pharmacy claims or hospital claims, because Italy has
a universal healthcare system (Trifirò et al., 2019). Indeed, several
studies have used these claims databases to evaluate antibiotic
use and safety in children (Lapi et al., 2010; Piovani et al., 2013;
Ferrajolo et al., 2019).
The antibiotics included in this study were the most
commonly used in pediatric patients in the year before the
study commenced (OsMed Report, 2015) and remain the most
commonly used antibiotics in 2017 (OsMed Report, 2018). The
purchase of antibiotics outside the NHS drug purchasing
pathway was always higher in Southern Italy, accounting for
approximately two-thirds of the purchase of amoxicillin, with the
implication being that it is not known whether this volume of
antibiotic purchasing occurred with or without any kind of
prescription. Indeed, there is a higher use of antibiotics among
children in the South of Italy compared to the North (OsMed
Report, 2018). This can be due to a range of reasons, the impact
of which unfortunately, cannot be ascertained. The purchase
of antibiotics outside the NHS drug purchasing pathway
may indicate the use of a non-NHS prescription from
a pediatrician in a private practice, or even of an NHS
prescription without request for reimbursement. It may also
indicate antibiotic purchase without any prescription at all. Non-
NHS prescriptions, often written by a specialist, would not make
patients eligible for reimbursement. On the other hand, the use
of NHS prescriptions which are not followed by a claim for
reimbursement may occur because, despite being eligible for full
or partial reimbursement, parents choose not to file a claim as the
medication price is very cheap, especially if the co-pay costs as
much as the medication reimbursement. This could be the case
for the amoxicillin, which is the cheapest antibiotic among our
study drugs. Indeed, the proportion of amoxicillin purchased
outside NHS pathway is much higher than that observed forFIGURE 2 | Antibiotic purchasing trends at the national level in Italy for pediatric formulations of the top five antibiotics used in children by calendar year.August 2020 | Volume 11 | Article 1232



































FIGURE 3 | Box plots of percentage of packages distribution purchased without a prescription for the top five antibio
Sultana et al. Pediatric Antibiotic Purchasing in Italyazithromycin, clarithromycin and cefixime. In addition,
amoxicillin is the first-line antibiotic therapy for common
infections in childhood, such as otitis, while macrolides are
recommended only in case of allergy to beta-lactam antibiotics
(Marchisio et al., 2019). Parents may therefore be more familiar
in using this antibiotic without a prescription as compared toFrontiers in Pharmacology | www.frontiersin.org 7other less commonly used antibiotics because it is likely to have
been previously prescribed. Indeed, a study conducted using the
Lombardy claims database showed that amoxicillin is by far the
most commonly used antibiotic among children compared to co-
amoxicillin, azithromycin, clarithromycin and cefuroxime
(Clavenna et al., 2010). From a pharmacological perspective, allFIGURE 4 | Relationship between medication price and the percentage of the top five pediatric antibiotic purchases without a prescription, along with Locally
Estimated Scatterplot Smoothing curves.August 2020 | Volume 11 | Article 1232
Sultana et al. Pediatric Antibiotic Purchasing in Italythe antibiotics included in the study are considered broad-
spectrum antibiotics in clinical practice (Gerber et al., 2017).
This is therefore unlikely to have affected the degree of out-of-
pocket purchases for the study drugs. The out-of-pocket
purchase of antibiotics may also indicate the purchase of
antibiotics after phone consultation with prescribers. Indeed, a
qualitative study in Italy showed that more than half of parents
admitted to giving antibiotics to their children only after a phone
consult with the prescriber, i.e. without an examination and
without a prescription, although this is not in line with Italian
prescribing policies (Bert et al., 2017). It should be noted that in
Italy, antibiotics should only be purchased with a prescription,
whether from an NHS prescriber or a prescriber from a private
practice. Nevertheless, the OsMed national report on antibiotic
use in 2017 showed that 17% of all antibiotics in Italy are
purchased outside the NHS drug purchasing pathway.
However, this analysis was not specifically conducted on such
purchasing trends in children (OsMed Report, 2018).
The reason behind the purchase of antibiotics outside the
NHS is difficult to ascertain using any source of secondary data.
Explanations of antibiotic purchasing behaviour outside of NHS
purchasing system can only be obtained via survey responses of
the parents making such purchases. In a survey of over 400
parents of primary school children in Central Italy, one-third of
all parents admitted to using antibiotics without a prescription,
while almost 25% of parents who had never purchased
antibiotics without a prescription said they would be willing to
do so (Napolitano et al., 2013). These figures are in line with
national findings from the present study that 24–29% of selected
antibiotic purchasing occurred without an NHS prescription
from 2015 to 2017, further increasing the plausibility that the
purchases without an NHS prescription reflect self-medication.
A more recent survey of parents’ knowledge and attitudes
concerning antibiotics was published in a wider catchment
area covering cities from Northern, Central and Southern Italy
(Bert et al., 2017). A quarter of parents in these areas admitted to
buying antibiotics for their children without a prescription
although no information on antibiotic preference was provided
(Bert et al., 2017). Indeed, self-medication in Italy has been
shown to be as high as 50% among a sample of almost 700
parents in central Italy (Garofalo et al., 2015). The importance of
monitoring antibiotic use diligently and systematically is
primarily related to the risk of antibiotic resistance. In
addition, misuse and over-use of antibiotics is associated with
potentially serious acute as well as long-term risks such as those
attributed to imbalances in gut microbiota, called dysbiosis. In
particular, frequent and inappropriate antibiotic use during
infancy may determine short- and long-term effects on the
diversity and composition of the gut microbiota which has
been associated with the onset of obesity, diabetes, asthma,
allergy and autoimmune disease later life (Vangay et al., 2015).
Another important finding of the present study was that
antibiotic purchase outside the NHS drug purchasing pathway
was generally correlated to product price, with lower prices
correlating to higher non-prescription purchases. However, we
also found that this correlation differs markedly from north toFrontiers in Pharmacology | www.frontiersin.org 8south Italy. The present study shows that the implementation of
any policies aiming to regulate antibiotic purchases would have
to take geographic area into account: it is only in Southern Italy
where there was a strong correlation between increasing drug
prices and decreasing purchases outside the NHS drug
purchasing pathway. This is likely due to the known
socioeconomic gradient in Italy, as Northern regions have a
better socioeconomic status than Southern ones. As a result,
persons in the South are likely to be less willing to pay a higher
price for antibiotics when purchasing them out-of-pocket, i.e.
without NHS reimbursement. Indeed, one of the World Health
Organisation’s policy recommendations to reduce antibiotic
resistance is to find a method of payment and reimbursement
that promotes compliance to treatment guidelines and
discourages irrational use (Leung et al., 2011). It may be worth
adding that the promotion of systematic data collection on all
antibiotic purchases is important in order to monitor whether
and to what extent such purchases occur within regulated and
appropriate purchasing pathways. In 2017, the Italian Ministry
of Health launched a national plan to reduce antibiotic
resistance, with one of the aims being the reduction of
systemic antibiotic use by at least 10% in the community
setting (Italian Ministry of Health, 2017). While the
commitment to improve antibiotic use surveillance in Italy has
improved, as can be seen by the yearly publication of the OsMed
national report on antibiotic use in Italy and in each region, it is
not year clear whether the objective of reducing unnecessary
antibiotic use has been achieved. If national plans to reduce
antibiotic resistance are to be effective, it is essential that the
various stakeholders, such as family pediatricians, specialists,
pharmacists, and parents, are continuously educated on the topic
and work together by respecting healthcare policies, in their
respective sphere.
The present study has several strengths. It is the first to
compare antibiotic purchasing pathways in Italian pediatric
patients longitudinally, i.e. non-NHS drug purchasing pathway
and the NHS drug purchasing pathway. This was done both at
the national level, as well as in specific geographic areas. The data
source used to do this, the Farma360 wholesale drug purchase
database, is one of the few that contains information on non-
NHS prescription purchases. A similar database has been used to
describe global antibiotic consumption, showing that medication
purchasing databases are both useful and reliable (Van Boeckel
et al., 2014). The analysis on the correlation between drug cost
and purchases outside the NHS drug purchasing pathway was
important to demonstrate that low cost is not always the main
driver of antibiotic purchasing outside a purchasing pathway
which offers drug reimbursement. We were also able to show that
the relationship between drug cost and antibiotic purchases
outside the NHS drug purchasing pathway varies across
geographic regions. It is possible, and indeed probable, that
such a correlation between out-of-pocket medication purchases
and price also exists for other medications. Similar studies at the
national level should be conducted to assess this, as it could have
important implications from a public health and pharmaceutical
policy perspective.August 2020 | Volume 11 | Article 1232
Sultana et al. Pediatric Antibiotic Purchasing in ItalyThis study also has some limitations. We have little
information concerning the purchase of antibiotics outside the
NHS drug purchasing pathway: we cannot know whether the
purchase was made with or without a prescription issued by
physicians in their private practice. We did not assume that such
purchases definitely constituted non-prescription purchases and
could not investigate the matter further. We also did not have
information on the indication of use for the selected antibiotics.
However, evaluating antibiotic appropriateness based on
indication was beyond the scope of this study, which was
limited to describing the purchases of antibiotics for pediatric
use in terms of transparency and traceability at a high level.
Finally, we did not have any patient-level information and were
therefore not able to describe the population purchasing the
study drugs.CONCLUSION
Almost a third of the top five most commonly used antibiotics with
pediatric formulations are purchased out-of-pocket. For amoxicillin,
this is as high as 60% in the South of Italy. As a result,
pharmacoepidemiologic studies using Italian claims databases,
which leverage the Italian NHS reimbursement system, risk
underestimating antibiotic use among children significantly. This
may lead to exposuremisclassification and potential bias. The private
purchase of these drugs increases with decreasing medication price,
especially in Southern Italy although the correlation was not strongly
linear. Lastly, our results could suggest the need for better monitoring
of antibiotic use within the NHS in order to reduce inappropriate
antibiotic use which would in turn reduce antibiotic-resistance. A
strategy is needed to improve antibiotic utilization monitoring, with
special emphasis on those drugs purchased outside the formal NHS
pathway, which are more likely to be inappropriately prescribed.
Public health interventions aimed at preventing antibiotic
purchasing without a prescription among healthcare professionals
and patients alike, are urgently needed.Frontiers in Pharmacology | www.frontiersin.org 9DATA AVAILABILITY STATEMENT
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